Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

ThinkEquity initiates Tharimmune stock with a Buy

EditorAhmed Abdulazez Abdulkadir
Published 01/04/2024, 12:12
THAR
-

On Monday, ThinkEquity initiated coverage on Tharimmune, Inc. (NASDAQ:THAR) with a Buy rating and a price target of $5.00. The firm highlighted Tharimmune's focus on developing innovative therapies for unmet medical needs in inflammatory and immunologic conditions. Tharimmune recently obtained an exclusive, worldwide license to advance and commercialize its key therapies, TH104 and TH103, through a partnership with Avior, Inc. in November 2023.

Tharimmune's lead product, TH104, employs a unique transmucosal buccal film delivery system, which allows the drug nalmefene to directly target μ-opioid and kappa opioid receptors, as well as inhibiting the IL-17 inflammatory cytokine. This novel therapeutic approach is designed to treat a variety of conditions associated with chronic itching, including liver-related diseases.

The company is poised to complete a phase 1 pharmacokinetic trial of TH104 in the second quarter of 2024. Following this, Tharimmune plans to conduct a phase 2 proof-of-concept study in patients with primary biliary cholangitis (PBC), aiming to finalize enrollment by the end of 2024, in line with FDA trial design discussions. TH104 is not only seen as a treatment for liver diseases but also has the potential to address chronic itching in several other conditions such as fatty liver, certain hepatitis types, chronic kidney diseases, hemodialysis, and atopic dermatitis.

Tharimmune has identified a significant market opportunity for TH104, which is expected to be competitively priced. The company's strategy targets a substantial market niche, with projected revenue potential for TH104 ranging from $350 million to $500 million from PBC alone, underlining the considerable financial prospects for the therapy in fulfilling this unmet medical need.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.